PASITHEA THERAPEUTICS CORP
KTTANASDAQTrading Snapshot
- Day Range
- $0.47 – $0.48
- 52-Week Range
- $0.28 – $2.06
- Volume
- $2.42B
- Avg Volume
- $2.09B
- Shares Outstanding
- 33.4M
- Next Earnings
- Sep 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $439,411
- P/E Ratio
- -0.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.81
- Dividend Yield
- 0.00%
Why Investors Own KTTA
- ✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PASITHEA THERAPEUTICS CORP
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 -- Full abstract will be published on ESMO website per Congress’ standard embargo schedule MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next
Pasithea Therapeutics To Present Phase I Dose-Escalation Study Of Safety, Pharmacokinetics Of PAS-004, Macrocyclic MEK Inhibitor, For Treatment Of MAPK Pathway Driven Advanced Solid Tumors At ESMO Congress 2026
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October
New Strong Buy Stocks for July 20th
KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2026.